Bristol Myers Squibb (BMY) Long-Term Deferred Tax (2009 - 2026)

Bristol Myers Squibb (BMY) has 18 years of Long-Term Deferred Tax data on file, last reported at $5.2 billion in Q1 2026.

• Quarterly Long-Term Deferred Tax rose 29.5% year-over-year to $5.2 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.2 billion (up 29.5% YoY) and the FY2025 annual result came in at $5.4 billion, up 26.96% from the prior year.
• Long-Term Deferred Tax eased to $5.2 billion in Q1 2026 per BMY's latest filing, from $5.4 billion in the prior quarter.
• Across five years, Long-Term Deferred Tax topped out at $5.4 billion in Q4 2025 and bottomed at $1.3 billion in Q1 2023.
• The 5-year median for Long-Term Deferred Tax is $2.8 billion (2023), against an average of $3.0 billion.
• The widest annual swing landed in 2023, when Long-Term Deferred Tax retreated 7.12%; it then soared 138.38% in 2024.
• Tracing BMY's Long-Term Deferred Tax over 5 years: stood at $1.3 billion in 2022, then soared by 105.95% to $2.8 billion in 2023, then soared by 53.03% to $4.2 billion in 2024, then rose by 26.96% to $5.4 billion in 2025, then declined by 3.76% to $5.2 billion in 2026.
• Per Business Quant, the three latest BMY Long-Term Deferred Tax figures stand at $5.2 billion (Q1 2026), $5.4 billion (Q4 2025), and $5.0 billion (Q3 2025).

Peer Comparison